For the quarter ended December 2023, United Therapeutics (UTHR) reported revenue of $614.7 million, up 25.1% over the same period last year. EPS came in at $4.36, compared to $2.67 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $561.77 million, representing a surprise of +9.42%. The company delivered an EPS surprise of +11.22%, with the consensus EPS estimate being $3.92.While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. “Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve our third straight quarter and second straight year of record revenue,” said Martine Rothblatt, Ph. ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 OR Delaware 52-1984749 (State or Other Jurisdiction of Incorporation or Organization) 1000 Spring ...

Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 21, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. "Congratulations to the dedicated Unitherians who worked t ...

Investors are always looking for stocks that are poised to beat at earnings season and United Therapeutics Corporation (UTHR) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because United Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possi ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider United Therapeutics (UTHR) . This company, which is in the Zacks Medical - Drugs industry, shows potential for another earnings beat.When looking at the last two reports, this drugmaker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 14.42%, on average, in the last two quarter ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 8, 2024, from 11:15 a.m. to 11:55 a.m., Pacific Standard Time, and can be ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.The presentation will take place on Monday, January 8, 2024, from 11:15 a.m. to 11:55 a.m., Pacific Standard Time, and can be a ...

Financial Performance - United Therapeutics reported total revenue of $609 million, an 18% increase year-over-year[19, 53] - Tyvaso (DPI and Nebulized) revenue reached $326 million, a 26% increase year-over-year[19, 53] - Remodulin revenue increased by 15% year-over-year to $131 million[19, 53] - Orenitram revenue increased by 5% year-over-year to $92 million, marking the second-highest revenue quarter for the product[19, 53, 57] - Unituxin revenue increased by 11% year-over-year to $51 million[19, 53] - The company's TTM (trailing twelve months) operating cash flow was $956 million[19] - United Therapeutics holds $4.9 billion in cash, cash equivalents, and marketable investments[19] Clinical Development & Pipeline - Enrollment is progressing in the TETON 1 and 2 studies for Tyvaso in Idiopathic Pulmonary Fibrosis (IPF), with approximately 60% and 50% enrollment, respectively, as of October 9, 2023[25] - The TETON PPF study for Tyvaso in Progressive Pulmonary Fibrosis (PPF) has enrolled its first patient in October 2023[27, 31] - The ADVANCE OUTCOMES study for Ralinepag in Pulmonary Arterial Hypertension (PAH) has enrolled over 510 patients as of October 1, 2023[37] Organ Manufacturing - United Therapeutics completed the acquisition of IVIVA Medical for $50 million, with a 2% royalty on any commercial sales[42] - The company anticipates the last xenokidney transplant in early 2024 and expects animal introduction in the first half of 2024 at the Designated Pathogen Free Facility (DPF)[45] - United Therapeutics has invested approximately $75 million in its Christiansburg, VA facility for xenotransplantation efforts, with construction completed in Q4/23[47]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1 ...